TAMPA, Fla. (July 17, 2026) — A team at the University of South Florida (USF) has uncovered a pathway that may help preserve heart function in people with Duchenne muscular dystrophy (DMD), a progressive and often fatal genetic disorder. The work, published in Molecular Therapy, focuses on cardiac decline, a major cause of morbidity as patients live longer with improved systemic care.
The researchers tested an experimental compound, Setanaxib, in two preclinical DMD models designed to mimic disease-related cardiomyopathy. Their central goal was to determine whether limiting biochemical stress inside cells could reduce inflammatory remodeling and subsequent loss of pumping capacity.
DMD results from mutations that disrupt production of functional dystrophin, a protein required to stabilize muscle cells under repeated mechanical stress. As dystrophin is absent, injury accumulates and healthy tissue is progressively replaced by fat and rigid scar. The heart is particularly vulnerable because continuous contraction drives ongoing damage.
In the new study, Setanaxib was engineered to reduce oxidative-stress signaling by targeting NOX1 and NOX4, enzymes that generate highly reactive molecules within cells. While controlled redox activity supports normal physiology, excessive production can promote inflammation and fibrosis—key hallmarks of DMD-associated cardiac injury.
Across the models, Setanaxib preserved the heart’s ability to pump blood and reduced both heart enlargement and fibrotic tissue formation. Molecular analyses further showed lowered expression of gene programs linked to cardiomyopathy, aligning functional improvements with changes at the transcriptional level.
The findings suggest that the NOX1/NOX4-driven pathway could be a tractable therapeutic axis for DMD heart disease. Rather than attempting to replace dystrophin directly, this strategy aims to interrupt downstream mechanisms that amplify tissue remodeling.
USF investigators note that a NOX4-targeting approach has already been evaluated in clinical research for fibrotic conditions affecting lung, kidney, and liver. This prior translational experience raises the possibility of faster therapeutic development for DMD patients, pending future safety and efficacy studies.
“Our results are very promising,” said John Mably, emphasizing the translational relevance of NOX4 inhibition. The study builds on more than 15 years of DMD research in Da-Zhi Wang’s laboratory, advancing an increasingly detailed map of disease progression mechanisms in cardiac tissue.
In parallel, the authors highlight that improved understanding of basic biomedical drivers can translate into therapies that protect organ function and improve quality of life for individuals affected by muscular dystrophy.
Subject of Research: People
Article Title: Treatment with the Nox1/4 inhibitor Setanaxib ameliorates cardiac function in mouse models of Duchenne muscular dystrophy
News Publication Date: July 17, 2026
Web References: https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(26)00510-1
References: 10.1016/j.ymthe.2026.06.033
Image Credits: USF Health
Keywords: Duchenne muscular dystrophy; cardiomyopathy; oxidative stress; NOX4; NOX1/4 inhibitor; Setanaxib; cardiac function; fibrosis; inflammation; preclinical models
Tags: biochemical stress management in muscular dystrophyDuchenne muscular dystrophy heart protectionexperimental treatments for DMD-related heart failureinflammation reduction in Duchenne muscular dystrophyinnovative approaches tomolecular therapy for muscle dystrophyNOX1 and NOX4 enzyme targeting for cardiac healthoxidative stress reduction in DMDpreclinical DMD models for heart failurepreserving cardiac function in genetic muscle disorderspreventing cardiac fibrosis in DMDSetanaxib in DMD cardiomyopathy
